Trials / Completed
CompletedNCT03380520
Effect of Intravenous FerRic carbOxymaltose oN Reverse Remodeling Following Cardiac Resynchronization Therapy
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 75 (actual)
- Sponsor
- Hasselt University · Academic / Other
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
To assess impact on left ventricular reverse remodeling defined as a change in left ventricular ejection fraction in heart failure patients with reduced ejection fraction (and previous implantation of cardiac resynchronization therapy) undergoing treatment with ferric carboxymaltose vs. placebo
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ferric Carboxymaltose | Ferric carboxymaltose will be administered according to product specification dosing |
| DRUG | Placebo | IV nacl 0.9% |
Timeline
- Start date
- 2017-10-01
- Primary completion
- 2020-12-31
- Completion
- 2021-08-04
- First posted
- 2017-12-21
- Last updated
- 2021-08-11
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT03380520. Inclusion in this directory is not an endorsement.